ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: A.M. Vitals: Texas Board to Vote on Stem-Cell Rules

(This story has been posted on The Wall Street Journal Online's Health Blog at By Mark Long Here's what's making health news this morning: Texas Eyes Change in Stem-Cell Rules (WSJ): The state's medical board will vote today on rules that would make it easier for physicians to offer treatments using adult stem cells. Bayer Said to Pay $110 Million in Yaz Birth-Control Cases (Bloomberg News): People familiar with the agreements told Bloomberg that the German drug maker will settle about 500 lawsuits claiming the pills caused blood clots. States Seek Curb on Patient Bills for Costly Drugs (New York Times): Lawmakers in at least 20 states have introduced bills to limit the amount patients with diseases that are expensive to treat have to pay out of pocket. Medicare to Settle Hospital Reimbursement Dispute (Los Angeles Times): The Centers for Medicare and Medical Services agreed to settle the dispute with about 2,200 hospitals over an error in reimbursement rates. Sexual Side Effects Added to Merck Drug Labels (Reuters): U.S. health regulators said the labels for a baldness treatment, Propecia, and one for enlarged prostate, Proscar, will note side effects that lasted after use of the drugs ended. Hospitals Drop Plan for Merger (WSJ): St. Anthony Medical Center and Rockford Memorial Hospital in Rockford, Ill., bowed to pressure from the FTC, which said a deal would make a local monopoly. Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease (Dow Jones Newswires): The multiple-sclerosis patient, diagnosed with often-fatal progressive multifocal leukoencephalopathy, had also been previously treated with another MS drug, Novartis said. -For continuously updated news from The Wall Street Journal, see at

Stock News for Novartis (NVS)
09/30/201519:04:00ADR Shares End Higher; JinkoSolar, Petrobras Trade Actively
09/30/201509:57:00United Therapeutics, Novartis Settle Dispute Over Generic Remodulin
09/25/201519:45:00Exelixis Reports Favorable Trial Results for Kidney Cancer Drug
09/23/201510:50:00Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive...
09/11/201516:21:00Novartis Heart Drug Overpriced, Group Says -- Update
09/11/201512:40:00Novartis Heart Drug Overpriced, Group Says
09/11/201512:26:00New Novartis Heart-Failure Drug Should Cost 17% Less, Research...
09/03/201513:11:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.--3rd...
09/03/201507:14:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S...
09/03/201505:24:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201504:00:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201502:49:00Novartis to Begin Selling Copy of Amgen's Neupogen in US
09/02/201516:30:00Novartis Closer to Selling Copy of Amgen's Neupogen
09/02/201516:22:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen...
09/02/201516:16:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen
09/02/201502:00:00Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs
09/01/201502:32:00Novartis Gets EU Approval For Skin Cancer Drugs Tafinlar, Mekinist
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/21/201509:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
08/21/201509:19:00Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations